1. Home
  2. Directory
  3. California
  4. Pleasanton
  5. Psychiatry Neurology
  6. NPI Profile
  7. Prescriptions 1700985413

LYNNE R. MIELKE M.D.
Prescription History 1700985413
Psychiatry & Neurology - Neurodevelopmental Disabilities in Pleasanton, CA

NPI Status: Active since September 21, 2006

Contact Information

4463 STONERIDGE DR STE A
PLEASANTON, CA
ZIP 94588
Phone: (925) 846-6300
Fax: (925) 846-6323

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for LYNNE R. MIELKE M.D., an active Neurodevelopmental Disabilities specialist practicing in Pleasanton, CA. Our medical registry currently tracks 4 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 84 documented patient claims. Among these therapy options, the most frequently utilized medication is Estradiol (Twice Weekly), which accounts for 28 claims alone.

Medication Index

Estradiol (Twice Weekly)

Generic Formulation: EstradiolSpecialty: Neuropsychiatry
Provider Metrics Summary
Total Claims 28
30-Day Fills 57.2
Days Supply 1,692
CA State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills49.8
Peer Average Days Supply1,469
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $3,836.26 across this reporting matrix range.

Provider Avg Cost Per Claim

$137.01

State Avg Cost Per Claim

$127.75

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids.

Therapeutic Applications

This medication is a female hormone (estrogen). It is used by women to help reduce symptoms of menopause (such as hot flashes, vaginal dryness). These symptoms are caused by the body making less estrogen. If you are using this medication to treat symptoms only in and around the vagina, products applied directly inside the vagina should be considered before medications that are taken by mouth, absorbed through the skin, or injected. This medication may also be used by women who are not able to produce enough estrogen (for example, due to hypogonadism, primary ovarian failure). Certain estrogen products may also be used by women after menopause to prevent bone loss (osteoporosis). However, there are other medications (such as raloxifene, bisphosphonates including alendronate) that are also effective in preventing bone loss and may be safer. These medications should be considered for use before estrogen treatment.

Levothyroxine Sodium

Generic Formulation: Levothyroxine SodiumSpecialty: Neuropsychiatry
Provider Metrics Summary
Total Claims 21
30-Day Fills 63.0
Days Supply 1,890
CA State Average Benchmarks
Peer Average Claims124.0
Peer Average 30-Day Fills305.1
Peer Average Days Supply9,029
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 83.1% less volume than the regional standard for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $357.74 across this reporting matrix range.

Provider Avg Cost Per Claim

$17.04

State Avg Cost Per Claim

$19.74

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

The major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (MONOIODOTYROSINE) and the coupling of iodotyrosines (DIIODOTYROSINE) in the THYROGLOBULIN. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form TRIIODOTHYRONINE which exerts a broad spectrum of stimulatory effects on cell metabolism.

Therapeutic Applications

Levothyroxine is used to treat an underactive thyroid (hypothyroidism). It replaces or provides more thyroid hormone, which is normally produced by the thyroid gland. Low thyroid hormone levels can occur naturally or when the thyroid gland is injured by radiation/medications or removed by surgery. Having enough thyroid hormone is important for maintaining normal mental and physical activity. In children, having enough thyroid hormone is important for normal mental and physical development. This medication is also used to treat other types of thyroid disorders (such as thyroid cancer). This medication should not be used to treat infertility unless it is caused by low thyroid hormone levels.

Liothyronine Sodium

Generic Formulation: Liothyronine SodiumSpecialty: Neuropsychiatry
Provider Metrics Summary
Total Claims 11
30-Day Fills 21.0
Days Supply 630
CA State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills61.7
Peer Average Days Supply1,833
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 59.3% less volume than the regional standard for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $706.38 across this reporting matrix range.

Provider Avg Cost Per Claim

$64.22

State Avg Cost Per Claim

$63.04

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A T3 thyroid hormone normally synthesized and secreted by the thyroid gland in much smaller quantities than thyroxine (T4). Most T3 is derived from peripheral monodeiodination of T4 at the 5' position of the outer ring of the iodothyronine nucleus. The hormone finally delivered and used by the tissues is mainly T3.

Therapeutic Applications

Liothyronine is used to treat an underactive thyroid (hypothyroidism). It replaces or provides more thyroid hormone, which is normally made by the thyroid gland. Liothyronine is a man-made form of thyroid hormone. Low thyroid hormone levels can occur naturally or when the thyroid gland is injured by radiation/medications or removed by surgery. Having enough thyroid hormone helps you stay healthy. For children, having enough thyroid hormone helps them grow and learn normally. This medication is also used to treat other types of thyroid problems (such as certain types of goiters, thyroid cancer). It can also be used to test for certain types of thyroid disease. This medication should not be used to treat infertility unless it is caused by low thyroid hormone levels.

Progesterone

Generic Formulation: Progesterone, MicronizedSpecialty: Neuropsychiatry
Provider Metrics Summary
Total Claims 24
30-Day Fills 64.0
Days Supply 1,920
CA State Average Benchmarks
Peer Average Claims29.0
Peer Average 30-Day Fills68.5
Peer Average Days Supply2,044
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,777.57 across this reporting matrix range.

Provider Avg Cost Per Claim

$74.07

State Avg Cost Per Claim

$54.36

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat infertility in women who do not make enough of a certain natural hormone called progesterone. This hormone is needed to maintain pregnancy. This medication is also used to restore menstrual cycles in women whose cycles have stopped. Progesterone is needed to keep menstrual periods regular.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like LYNNE R. MIELKE M.D. provides transparency into local medical care patterns within Pleasanton, CA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Neurodevelopmental Disabilities** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.